Cancer Clinical Trial - Toray 950P1V02

Status:

Open

ClinicalTrials.gov:

NCT03872947

CONDITION(S): Advanced Solid Tumors, Ovarian, Gastric, Bladder, Colorectal - TRIAL: Toray 950P1V02 - A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream for selected advanced solid tumors.

Drug

Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream

Trial Type

Interventional

Condition

Advanced solid tumors Ovarian cancer Gastric cancer Bladder cancer Colorectal cancer

Keywords

Advanced solid tumors | Ovarian cancer | Gastric cancer | Bladder cancer | Colorectal cancer